The current state of molecular testing in the BRAF-mutated melanoma landscape
I Vanni, ET Tanda, F Spagnolo, V Andreotti… - Frontiers in Molecular …, 2020 - frontiersin.org
The incidence of melanoma, among the most lethal cancers, is widespread and increasing.
Metastatic melanoma has a poor prognosis, representing about 90% of skin cancer …
Metastatic melanoma has a poor prognosis, representing about 90% of skin cancer …
Translational application of circulating DNA in oncology: review of the last decades achievements
NO Tuaeva, L Falzone, YB Porozov, AE Nosyrev… - Cells, 2019 - mdpi.com
In recent years, the introduction of new molecular techniques in experimental and clinical
settings has allowed researchers and clinicians to propose circulating-tumor DNA (ctDNA) …
settings has allowed researchers and clinicians to propose circulating-tumor DNA (ctDNA) …
Antifouling electrochemical biosensor based on the designed functional peptide and the electrodeposited conducting polymer for CTC analysis in human blood
R Han, Y Li, M Chen, W Li, C Ding, X Luo - Analytical Chemistry, 2022 - ACS Publications
Circulating tumor cells (CTCs) are considered reliable cancer biomarkers for the liquid
biopsy of many types of tumors. The direct detection of CTCs in human blood with normal …
biopsy of many types of tumors. The direct detection of CTCs in human blood with normal …
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma–results of a prospective biomarker study
A Forschner, F Battke, D Hadaschik, M Schulze… - … for Immunotherapy of …, 2019 - Springer
Background Metastasized or unresectable melanoma has been the first malignant tumor to
be successfully treated with checkpoint inhibitors. Nevertheless, about 40–50% of the …
be successfully treated with checkpoint inhibitors. Nevertheless, about 40–50% of the …
Clinical utility of plasma cell-free DNA in adult patients with newly diagnosed glioblastoma: a pilot prospective study
SJ Bagley, SA Nabavizadeh, JJ Mays, JE Till… - Clinical Cancer …, 2020 - AACR
Purpose: The clinical utility of plasma cell-free DNA (cfDNA) has not been assessed
prospectively in patients with glioblastoma (GBM). We aimed to determine the prognostic …
prospectively in patients with glioblastoma (GBM). We aimed to determine the prognostic …
Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients
GT Marczynski, AC Laus, MB Dos Reis, RM Reis… - Scientific Reports, 2020 - nature.com
Abstract BRAF, NRAS and TERT mutations occur in more than 2/3 of melanomas. Its
detection in patient's blood, as circulating tumor DNA (ctDNA), represents a possibility for …
detection in patient's blood, as circulating tumor DNA (ctDNA), represents a possibility for …
Leveraging the fragment length of circulating tumour DNA to improve molecular profiling of solid tumour malignancies with next-generation sequencing: a pathway to …
HR Underhill - Molecular diagnosis & therapy, 2021 - Springer
Circulating cell-free DNA (ccfDNA) has emerged as a promising diagnostic tool in oncology.
Identification of tumour-derived ccfDNA (ie circulating tumour DNA [ctDNA]) provides non …
Identification of tumour-derived ccfDNA (ie circulating tumour DNA [ctDNA]) provides non …
Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition
C Schroeder, S Gatidis, O Kelemen, L Schütz… - Nature …, 2024 - nature.com
Immune checkpoint inhibitors (ICI) have significantly improved overall survival in melanoma
patients. However, 60% experience severe adverse events and early response markers are …
patients. However, 60% experience severe adverse events and early response markers are …
Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanoma
R Váraljai, K Wistuba-Hamprecht, T Seremet… - JCO precision …, 2019 - ascopubs.org
PURPOSE Circulating cell-free tumor DNA (ctDNA) reflects the heterogeneous spectrum of
tumor-specific mutations, especially in systemic disease. We validated plasma-based …
tumor-specific mutations, especially in systemic disease. We validated plasma-based …
Melanoma: genetic abnormalities, tumor progression, clonal evolution and tumor initiating cells
U Testa, G Castelli, E Pelosi - Medical Sciences, 2017 - mdpi.com
Melanoma is an aggressive neoplasia issued from the malignant transformation of
melanocytes, the pigment-generating cells of the skin. It is responsible for about 75% of …
melanocytes, the pigment-generating cells of the skin. It is responsible for about 75% of …